Vext Science, Inc.

Vext Science, Inc.

VEXTF
Vext Science, Inc.US flagOther OTC
0.18
USD
-0.01
- -
44.38MMarket Cap
2017 Y
2018 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.8
0.99
0.99
0.28
0.27
0.27
0.26
0.21
0.15
0.21
0.3
Basic EPS, GAAP
0.22
0.2
0.2
0.04
0.02
0.04
0.08
0.03
-0.09
-0.07
-0.09
Free Cash Flow per Basic Share
0.04
0.05
0.05
-0.07
-0.01
-0.06
-0.02
0.01
0.01
0.03
0.04
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.47
0.89
0.89
0.32
0.37
0.41
0.49
0.51
0.28
0.2
0.27
Tangible Book Value per Share
0.47
0.91
0.91
0.33
0.31
0.38
0.31
0.17
0.02
-0.04
-0.05
Basic Weighted Avg Shares
19
19
19
79
93
137
139
164
241
248
173
Sales/Revenue/Turnover
15
18
18
22
25
37
35
35
36
51
52
Operating Margin (%)
38.53
30.47
30.47
16.05
13.33
24.73
26.22
-22.53
-31.06
-13.51
-9.24
Depreciation Expense
- -
1
1
1
2
3
6
10
15
16
16
Net Income, GAAP
4
4
4
3
2
5
11
4
-22
-18
-16
Effective Tax Rate (%)
27.12
23.19
23.19
23.85
19.48
26.88
- -
- -
- -
- -
659.85
Profit Margin (%)
27.66
20.29
20.29
12.51
8.43
13.39
30.84
12.63
-62.32
-35.03
-29.93
Working Capital
8
15
15
22
15
21
36
20
1
-12
-10
LT Debt
1
- -
- -
6
5
8
32
32
34
27
26
Total Equity
9
17
17
26
36
59
72
93
73
55
54
Return on Invested Capital (%)
- -
1,089.65
1,089.65
14.53
6.69
11.1
- -
- -
- -
- -
- -
Return on Capital (%)
- -
27.04
27.04
11.34
6.96
11.37
- -
- -
- -
- -
29.83
Return on Common Equity (%)
- -
29.46
29.46
13.44
7.14
10.98
17.6
5.81
-29.94
-31.36
-27.52

Capital Structure

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
3
8
8
LT Borrowings
30
24
23
LT Finance Leases
2
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
248
248
248
Market Capitalization
90
65
43

Working Capital

FRC

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
16
17
17
Cash, Cash Equivalents & STI
4
5
6
Accounts Receivable, Net
1
1
- -
Inventories
10
7
9
Total Current Liabilities
17
28
27
Payables & Accruals
14
20
19
ST Debt
3
8
8
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
13.62%
-24.48%
Free Cash Flow
- -
164.51%
346.55%
Net Income, GAAP
- -
-87.19%
-19.79%
Sales/Revenue/Turnover
- -
17.46%
42.69%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
8
8
9
10
36
2025
12
13
13
14
51
2026
12
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.02
-0.01
- -
-0.09
2025
-0.01
-0.01
-0.01
- -
-0.07
2026
-0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Eric J. Offenberger
Full Time Employees
173
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
4152 North 39th Avenue Phoenix AZ Canada 85019
IPO Date
May 28, 2019
Business
Vext Science, Inc. operates as an integrated agricultural technology, services, and property management company within the cannabis industry in the United States. The company manufactures, sells, and manages cannabis THC and hemp CBD products, including THC concentrates, edibles, distillate cartridges, and related branded merchandise. Its core product portfolio features the Vapen brand, which is a leading line of THC concentrates, edibles, and distillate cartridges produced using the company's in-house grown, high-quality flower. Vext also markets products under the Pure Touch, Appalachian Pharm, Herbal Wellness, and Revibe brands. The company owns and operates state-of-the-art cultivation facilities, fully equipped manufacturing units, and retail dispensaries primarily located in Arizona and Ohio. It provides additional services such as management, advisory, cultivation, non-cannabis product offerings, and dispensary operations through direct sales and joint operational agreements. Founded in 2015 and headquartered in Phoenix, Arizona, Vext Science focuses on vertically integrated cannabis operations across key U.S. markets, leveraging its cultivation, manufacturing, branding, and retail capabilities. Recent major company developments include the expansion of its retail footprint in Ohio to five consolidated dispensary locations with regulatory approval to reach the state's dispensary license cap of eight by 2026. This expansion underpins significant revenue growth, with the company reporting a 41% year-over-year revenue increase to $12.7 million driven by Ohio operations and steady performance in Arizona. The company completed the acquisition of the Herbal Wellness Center dispensary in Portsmouth, Ohio, in October 2025, further strengthening its market presence. Vext continues to focus on operational discipline and growth through new dispensary construction, licensing advances, and product innovation, positioning itself for sustainable, profitable expansion in its core states. Vext Science serves a broad customer base through its diversified cannabis product offerings and retail dispensary network, operating in the specialty drug manufacturing and healthcare sectors. Its leadership maintains a proven track record in building and operating profitable multi-state cannabis operations, emphasizing high-quality product development and effective market penetration in the adult-use cannabis market. The company was formerly known as Vapen MJ Ventures Corporation until its name change to Vext Science, Inc. in November 2019. It operates within the U.S. cannabis market with an ongoing strategic focus on growth, innovation, and market share expansion in both cultivation and retail segments. Recent operational excellence and financial performance improvements highlight its trajectory toward sustained market leadership in Arizona and Ohio.

Company News

APIChatGPT
  • Vext Opens Sixth Ohio Dispensary in Fairfield

  • Vext Science Inc. (VEXTF) Q1 2026 Earnings Call Transcript

  • Vext Reports Q1 2026 Financial Results; Adjusted EBITDA up 73% Sequentially to $3.6 Million as Ohio Platform Scales

  • Vext Engages Zuanic & Associates

  • Vext Announces Date for Q1 2026 Financial Results Release

  • Vext Science Inc. (VEXTF) Q4 2025 Earnings Call Transcript

  • Vext Reports Q4 and FY 2025; Fiscal 2025 Revenue up +43% to $51.4M, Operating Cash Flow up +256% to $11.7M as Ohio Retail Scales

  • Vext Announces Revised Date for Q4 and Fiscal 2025 Financial Results Release

  • Vext Science Announces Strategic Optimization of Arizona Operations and Plans for Ohio Cultivation Expansion

  • Vext Advances Ohio Expansion with Seventh Retail Location

  • Vext Science (OTCMKTS:VEXTF) Stock Price Up 14.2% – What’s Next?

  • Vext Announces Voting Results of Annual General Meeting

  • CORRECTION FROM SOURCE: Vext Reports Q3 2025 Financial Results

  • Vext Science Inc. (VEXTF) Q3 2025 Earnings Call Transcript

  • Vext Reports Q3 2025 Financial Results; Revenue Up 41% Year-over-Year and Operating Cash Flow Year-To-Date Reaches $8.5 Million

  • Vext to Announce Financial Results for Q3 2025 on November 20, 2025

  • Vext Secures State Approval for Portsmouth Dispensary Ownership Transfer

  • Vext Science Inc. (VEXTF) Q2 2025 Earnings Call Transcript

  • Vext Announces Q2 2025 Financial Results: Record Quarterly Revenue with Strong 31% Cash Flow Margin

  • Vext to Announce Financial Results for Q2 2025 on August 20, 2025